From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Patients | Trial, ID | Follow-up | Outcomes | Reference |
---|---|---|---|---|
Advanced melanoma | Phase 1 NCT01024231 | ≥24 weeks | ORR, 53% Grade 3-4 AEs, 53% | Wolchok et al 2013 |
Previously untreated advanced melanoma | Phase 1 NCT01927419 | ≥11 months | In patients with BRAF-WT tumors ORR 61% Median PFS, not reached HR for disease progression or death, 0.40 Grade 3-4 AEs, 54% | Postow et al 2015 |
Previously untreated advanced melanoma | Phase 3 NCT01844505 | > 12 months | Median PFS, 11.5 months HR for death or disease progression, 0.42 Investigator assessed ORR, 57% Grade 3-4 AEs, 55% | Larkin et al 2015 |
Previously untreated advanced melanoma | Phase 3 NCT01844505 | ≥ 36 months | Median OS, not reached 3-year OS rate, 58% HR for death, 0.55 Grade 3-4 AEs, 59% | Wolchok et al 2017 |
Previously untreated advanced melanoma | Phase 3 NCT01844505 | ≥ 48 months | Median OS, not reached 4-year OS rate, 54% ORR, 58% HR for death, 0.54 HR for progression-free survival, 0.42 Grade 3-4 AEs, 59% | Hodi et al 2018 |
Advanced melanoma patients with at least one brain metastasis | Phase 2 NCT02320058 | ≥ 6 months | Rate of intracranial clinical benefit, 57%; Rate of extracranial clinical benefit, 56% 9-month PFS (global) rate, 57%; 9-month OS rate, 83 12-month OS rate, 82% Grade 3-4 AEs, 55% | Tawbi et al 2018 |
Advanced melanoma | Phase 2 NCT01783938 | ≥ 15 months | ORR, 56% Median OS, not reached 1-year OS rate, 76% Grade 3-5 AEs, 50% | Weber et al 2018 |
Previously untreated advanced clear cell renal cell carcinoma | Phase 3 NCT02231749 | > 17 months | ORR, 42% Median OS, not reached HR for death, 0.63 Median PFS, 11.6 months HR for disease progression, 0.82 | Motzer et al 2018 |
Previously treated, MMR/MSI-H positive advanced colorectal cancer | Phase 2 NCT02060188 | > 9 months | ORR, 55% Median PFS, not reached 12-month PFS rate, 71% Median OS, not reached 12-month OS rate, 85% Grade 3-4 AEs, 32% | Overman et al 2018 |